Last update Nov. 15, 2015
INon-glycosylated stimulating factor of granulocyte colonies (G-CSF) which is obtained by recombinant technology. It is practically identical to the naturally occurring product that is found in the breast milk.
It is indicated for the treatment of cancer-related neutropenia, and autologous bone marrow transplantation.
At last update no published data on excretion in breast milk were found.
A high molecular weight makes unlikely its excretion into breastmilk in a significant amount.
Its low oral bioavailability hampers absorption into infant plasma from the breast milk ingested, as for their proteic nature it is degraded in the gastrointestinal tract, not being absorbed.
Other substances similar in composition and action as Filgrastim and Lenograstim are excreted into breast milk in trace amounts and have been used to treat sepsis and necrotizing enterocolitis in newborn and premature without harmful effects in the infants.
Until more data about this drug regarding breastfeeding is obtained, alternatives that are known to be safer should be preferable, especially during the neonatal period and/or in case of prematurity.
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Asociación Española de Bancos de Leche Humana of Spain
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM